Pharma News

Poniard Pharma suspends efforts to obtain regulatory approval for picoplatin in SCLC

 Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, announced a clinical and regulatory update on its lead product candidate, picoplatin. Following a detailed analysis of primary and updated data from the phase 3 SPEAR study of picoplatin in small cell lung cancer (SCLC) and an evaluation of the ongoing New Drug Application (NDA) process with the US Food and Drug Administration (FDA), the company has decided to suspend its efforts to obtain regulatory approval for picoplatin in SCLC at this time.

NIH creates new genetic testing registry to help researchers, consumers & healthcare providers

 The National Institutes of Health (NIH) announced that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers. The Genetic Testing Registry (GTR) aims to enhance access to information about the availability, validity, and usefulness of genetic tests.

PCI clarifies its notification on MS not specific on NIPER's course

 Entailing the ongoing controversy over the recognition of Master of Pharmacy (MS) programme offered by National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Pharmacy Council of India (PCI) has come out with a clarification that the NIPER's MS programme has not been specifically commented anytime by the council and is not an issue under the consideration of the body.

Syngene, Endo Pharmaceuticals in oncology deal

 Bangalore, Mar, 23, 2010: Syngene International, a subsidiary of Biocon has entered into a discovery and development collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer.

Under the agreement Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.

 

Pages